Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Personalized Therapeutics Moving Beyond Precision Medicine, 5/14/2021 8:00:00 AM - 5/14/2024 9:00:00 AM, Participants in Medicine Grand Rounds will be able to identify the most current treatment guidelines, innovations, and standards of practice, and apply them to improve the care of individual patients, promote health and wellness in the population, and achieve clinical quality and safety goals. These educational activities are grounded in principles of health equity, evidence based medicine, inter-professional teamwork, patient-centered care, and respect for human dignity.
Presenter
Lionel D. Lewis, MA, MB.BCh, MD, FRCP (London), FBPhS
Professor of Medicine & Pharmacology
Geisel School of Medicine at Dartmouth
About our Presenter
Dr. Lionel Lewis received his BA and MA from Trinity College Cambridge, England in medical sciences and biochemistry, and his clinical training in Medicine at the University of Wales, College of Medicine, graduating Bachelor of Medicine /Bachelor of Surgery (MB.BCh). He earned his Doctorate in Medicine (MD) from the University of Wales and was then a Fellow in Clinical Pharmacology at The Johns Hopkins Hospital. Dr. Lewis is a full Professor of Medicine, Pharmacology & Toxicology. He is the Director of the NCCC Clinical Pharmacology Shared Resource and Medical Director of the Dartmouth-Hitchcock Clinical Trials Office. Currently, Dr. Lewis serves as our Section Chief of Clinical Pharmacology and Toxicology in the Department of Medicine.
Learning Outcome(s)
Participants will be able to discuss what adaptive dosing is and its relevance in bone marrow transplant patients, and be able to analyze and interpret treatment studies in patients with renal and hepatic dysfunction.
Disclosure
In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.
The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have reported the following financial interest or relationship* with various companies/organizations. The Planning Committee member role was resolved by altering the individual’s control over content about the products or services of the commercial interest by Marc Bertrand, MD, Associate Dean for GME (as alternate for vacant Associate Dean for CME position). The speaker conflicts have been resolved by validating the activity content through independent peer review by Kelly Kieffer, MD. All potential conflict(s) were resolved.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
* Lionel D. Lewis, MA, MB.BCh, MD, FRCP (London), FBPhS ~ reports receiving research grants from the following companies: Amgen, Bristol Myers, Squibb, Abbvie, Novartis, Genentech, DARPA and NINDs. He is also a consultant for USA CDMRP, G1 Therapeutics, Inc, and 7 Hills Pharma, LLC.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.
*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Presenter
Lionel D. Lewis, MA, MB.BCh, MD, FRCP (London), FBPhS
Professor of Medicine & Pharmacology
Geisel School of Medicine at Dartmouth
About our Presenter
Dr. Lionel Lewis received his BA and MA from Trinity College Cambridge, England in medical sciences and biochemistry, and his clinical training in Medicine at the University of Wales, College of Medicine, graduating Bachelor of Medicine /Bachelor of Surgery (MB.BCh). He earned his Doctorate in Medicine (MD) from the University of Wales and was then a Fellow in Clinical Pharmacology at The Johns Hopkins Hospital. Dr. Lewis is a full Professor of Medicine, Pharmacology & Toxicology. He is the Director of the NCCC Clinical Pharmacology Shared Resource and Medical Director of the Dartmouth-Hitchcock Clinical Trials Office. Currently, Dr. Lewis serves as our Section Chief of Clinical Pharmacology and Toxicology in the Department of Medicine.
Learning Outcome(s)
Participants will be able to discuss what adaptive dosing is and its relevance in bone marrow transplant patients, and be able to analyze and interpret treatment studies in patients with renal and hepatic dysfunction.
Disclosure
In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.
The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have reported the following financial interest or relationship* with various companies/organizations. The Planning Committee member role was resolved by altering the individual’s control over content about the products or services of the commercial interest by Marc Bertrand, MD, Associate Dean for GME (as alternate for vacant Associate Dean for CME position). The speaker conflicts have been resolved by validating the activity content through independent peer review by Kelly Kieffer, MD. All potential conflict(s) were resolved.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
* Lionel D. Lewis, MA, MB.BCh, MD, FRCP (London), FBPhS ~ reports receiving research grants from the following companies: Amgen, Bristol Myers, Squibb, Abbvie, Novartis, Genentech, DARPA and NINDs. He is also a consultant for USA CDMRP, G1 Therapeutics, Inc, and 7 Hills Pharma, LLC.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.
*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
